All In Biotech

Drug Trial Radar · NCT05238493

A Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VEL-101

A Phase 1, Randomized, Double Blind, Placebo Controlled, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VEL-101 Administered Intravenously or Subcutaneously in Healthy Subjects.

Last checked: Nov 19, 2026Latest source record: Jun 27, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

60

Actual

Start

Apr 26, 2022

Primary completion

Jan 3, 2023

Study completion Jan 3, 2023

Sponsor

Lead sponsor
Asahi Kasei Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Feb 14, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Other
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study is primarily designed to assess the safety and tolerability of single doses of VEL-101 when administered subcutaneously (via injection into an area under the skin) or intravenously (via infusion into a vein). As each new group of participants is enrolled into the study, the dose administered to that group may be higher than a previous dose shown to be safe in other participants. The study is also designed to determine blood levels of VEL-101 and some substances produced by the immune system following VEL-101 administration. This information can provide insight into how quickly VEL-101 is eliminated from the body and some if its effects on the body.

Conditions

  • Healthy Volunteers

Interventions

  • VEL-101Drug

    Intervention administered via subcutaneous injection or 1-hour intravenous infusion on Day 1

  • PlaceboDrug

    Intervention administered via subcutaneous injection or 1-hour intravenous infusion on Day 1

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number and Percentage of Participants with Treatment-emergent Adverse Events (TEAEs)Time frame: Day 1 through Day 50
  2. Number and Percentage of Participants with Serious TEAEsTime frame: Day 1 through Day 50
  3. Number and Percentage of Participants with Grade 3 or Higher TEAEsTime frame: Day 1 through Day 50
  4. Number and Percentage of Participants with TEAEs Leading to Withdrawal from the StudyTime frame: Day 1 through Day 50
  5. Number and Percentage of Participants with TEAEs Leading to DeathTime frame: Day 1 through Day 50

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • CTI Clinical Research Center

    Cincinnati, Ohio

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.